Substance use disorder Flashcards

1
Q

Addiction

General

A

is a primary, chronic disease of brain reward, motivation, memory and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, and social manifestations.

Addiction affects neurotransmission and interactions within reward structures of the brain, including….
The nucleus accumbens (the “reward center”)
The anterior cingulate cortex (ACC)
The basal forebrain
The amygdala

Genetic factors account for about half of the likelihood that an individual will develop addiction

The presence of co-occurring psychiatric disorders in persons who engage in substance use or other addictive behaviors
ADHD, Anxiety Disorders, Depressive Disorders, Personality Disorders, Bipolar Disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

addiction

patho- Reward

A

In a “normal brain” dopamine is released from the ACC to the NC when we do things that promote survival (drinking water, eating food, having sex, and sleeping) as a positive reinforcement mechanism.

Various substances, including all of the most commonly abused substances, hijack this system by releasing significantly higher levels of dopamine from the ACC into the NC, and for a greater duration of time. After this occurs, victims are now much more likely to repeat the behavior as nothing else is able to produce that type of euphoria - their reward center has been introduced to a new threshold of pleasure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Addiction

Patho- Memory

A

Addiction also affects neurotransmission and interactions between….
The cortical and hippocampal circuits and the nucleus accumbens, such that the memory of previous exposures to rewards (such as heroin) leads to a biological and behavioral response to external cues → triggering craving and/or engagement in addictive behaviors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Addiction

Pathophysiology - The Frontal Lobe & Cortex

A

Frontal lobe is responsible for:
Storing negative consequences to avoid poor actions in the future
Inhibiting impulsivity and appropriately delay gratification

Patients with addiction have a severely underdeveloped frontal lobe. Meaning high impulsivity and difficulty recognizing consequences of poor choices.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Addiction

Pathophysiology - summary

A

Inactive front lobe
(decreased impulse control and decreased ability to utilize learned social behavior and logic)
+
Hyperactive reward center
(which now has a new standard for gratification)
=
a patient with very little control over their drug use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Addiction

Genetics

A

Resiliencies which the individual acquires (through parenting or later life experiences) can affect the extent to which genetic predispositions lead to the behavior and other manifestations of addiction

Patients can be born with underlying biological deficits in the function of reward circuits resulting in a exaggerated reward response within the NA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Substance abuse Disorder DSM Criteria

A

A problematic pattern of “substance” use leading to clinically significant impairment or distress, as manifested by at least 2 of the following, occuring within a 12 month period:

  • Substance is taken in larger amounts or over a longer period than was intended
  • There is a persistent desire or unsuccessful efforts to cut down or control substance use.
  • A great deal of time is spent in activities necessary to obtain, use, or recover from it’s effects
  • Craving, or a strong desire or urge to use the substance
  • Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home
  • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance
  • Important social/work/ rec activities are given up or reduced because of use
  • Recurrent use in situations in which it is physically hazardous
  • Use is continued despite knowledge of having a persistent or recurrent physical or psych problem that is likely to have been caused or worsened by substance
  • Tolerance
  • Withdrawal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SUD

Specifiers and severity

A

Specifiers
In early remission: no criteria met for at least 3 months, but less than 12 (except cravings)
In sustained remission: no criteria met for 12 months (except cravings)
In controlled environment

Severity
Mild: 2-3 symptom criteria met
Moderate: 4-5
Severe: 6+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Alcohol Use Disorder

RF

A

Family history of alcohol use disorder and other substance use disorders
Availability of alcohol
Heavy alcohol use
Binge drinking
Permissive societal attitudes towards alcohol use
History of childhood abuse
History of conduct or mood disorder in childhood
Having mental health conditions such as depression or post-traumatic stress disorder
Impulsivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Alcohol Use Disorder

At-Risk Drinking criteria

A

At-Risk Drinking:
Men: more than 4 drinks/day, or more than 14 drinks/week

Women: more than 3 drinks/day, or more than 7 drinks/week

Men and Women over age 65: More than 3 drinks/day, or more than 7 drinks/week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

alcohol use disorder

Binge Drinking criteria

A

Men: 5 or more drinks in a 2- to 3-hour period

Women: 4 or more drinks in a 2- to 3-hour period

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Alcohol use disorder

SCREENING

A

AUDIT - 10 question - best screening tool
CAGE - 4 questions (cut down, annoyed, guilty, eye-opener)
MAST - 25 question

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

AUD

comorbidities

A

Repeated use in high amounts can impair nearly every organ system
Gastritis
Stomach/duodenal ulcers
Liver cirrhosis
Pancreatitis
Esophageal and stomach cancer
Hypertension
Cardiomyopathies, hypertriglyceridemia, elevated LDL
Myopathies
Severe memory impairment
Degenerative changes in the cerebellum
Thiamine deficiency → Wernicke-Korsakoff Syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AUD

Lab markers

A

BAC, or blood alcohol concentration: (>200mg/dL in any non-tolerant pt should demonstrate severe intox)
GGT (gamma-glutamyltransferase) - high-normal - About 70% of patients with elevated GGT are persistently heavy drinkers (8+ per day)
CDT (carbohydrate-deficient transferrin) - levels of 20 units or higher can be useful in identifying individuals who drink/abuse alcohol regularly
MCV - high-normal, but not a good predictor of abstinence due to long lifespan of RBC’s
LFT’s - AST:ALT ratio > 2:1 is indicative of heavy alcohol use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Alcohol Intoxication

general

A

Slurred speech, Incoordination, Unsteady gait, Nystagmus, Impairment in attention/memory, Stupor/coma

BAC over 300-400 mg/dL can cause inhibition of respiration → death

In general, the body is able to metabolize about 1 drink per hour and BAC should fall about 15-20mg/dL per hour

THERE IS A SIGNIFICANTLY INCREASED RATE OF SUICIDE DURING ALCOHOL INTOXICATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AUD -tx

Acamprosate (Campral)

A

666mg 3x daily (initial and therapeutic dose) - start lower if renal impairment is present
No labs required, but should be avoided in patients with severe renal impairment

Glutamate neurotransmission modulation at metabotropic-5 glutamate receptor sites

MC side effects: diarrhea, nervousness, and fatigue
Can take with naltrexone and disulfiram and in pts who continue to drink

Contraindication: severe renal impairment (CrCl 30 or less)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

AUD - tx

Naltrexone (mu opioid receptor blocker)

A

Partial antagonist

50mg PO once daily or 380mg IM q4wks
Requires monitoring of LFTs q 6months

Mice that lack the mu-opioid receptor do not self-administer alcohol

Naltrexone also modifies the HPA axis to suppress ethanol consumption
Reduces heavy drinking by only about 25%

Contraindication: acute hepatitis and liver failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

AUD

Disulfiram (Antabuse)

A

125-500mg once daily
discourages drinking by causing an unpleasant physiologic reaction when alcohol is consumed
Inhibits aldehyde dehydrogenase and prevents the metabolism of alcohol’s primary metabolite, acetaldehyde

Results in sweating, headache, dyspnea, lowered blood pressure, flushing, sympathetic overactivity, palpitations, nausea, and vomiting if alcohol were to be consumed

initially dosed at 500 mg/day for 1-2 weeks, followed by an avg maintenance dose of 250 mg/day with a range from 125-500 mg based on the severity of adverse effect
Side effects; rash, drowsiness, HA, metallic taste, hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

AUD

Disulfirm- contraindications

A

Contraindications: severe myocardial disease and/or coronary occlusion, psychosis, or known hypersensitivity to the medication or other thiuram derivatives. Also avoid in pregnancy and during breastfeeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Alcohol Withdrawal

Sx

A

2 or more of the following begin shortly after cessation of prolonged drinking:
Autonomic hyperactivity (diaphoresis, tachycardia)
Increased hand tremor
Insomnia
nausea/vomiting
Transient hallucinations
Psychomotor agitation
Anxiety
Generalized tonic-clonic seizures (6 - 48 hours after last drink)

WITHDRAWAL FROM ALCOHOL CAN BE LETHAL
Tx short term acute symptoms with low dose benzodiazepines

21
Q

AUD

CIWA

A

Withdrawal assessment

22
Q

AUD

Alcohol withdrawal in severe cases

A

Alcoholic hallucinosis - visual, auditory, and/or tactile hallucinations with intact orientation and normal vital signs; 12-48 hours after last drink

Delirium Tremens - delirium, agitation, tachycardia, hypertension, fever, diaphoresis; 48-96 hours after last drink. Can be LETHAL

23
Q

Wernicke-Korsakoff Syndrome - thiamine (B1) deficiency

Wernicke encephalopathy (WE)

A

Wernicke encephalopathy (WE) is an acute syndrome requiring emergent treatment to prevent death and neurologic morbidity.

S/s: encephalopathy, oculomotor dysfunction, and gait ataxia.
Atrophy of the mamillary bodies is a relatively specific sign of prior WE

Acute

24
Q

Wernicke-Korsakoff Syndrome - thiamine (B1) deficiency

Korsakoff syndrome (KS)

A

Korsakoff syndrome (KS) refers to a chronic neurologic condition that usually occurs as a consequence of WE

disorder of selective antegrade and retrograde amnesia (d/t lesions in the anterior thalamus), apathy, an intact sensorium, and relative preservation of long-term memory and other cognitive skills

Patients with KS rarely recover

chronic

25
Q

Wernicke

Tx

A

The diagnosis of WE is difficult to confirm and, untreated, most patients progress to coma and death
Testing should not delay tx, so **if suspected immediately give thiamine **

A recommended regimen is 500 mg of thiamine IV, infused over 30 minutes, 3x daily for 2 consecutive days and 250 mg IV or IM once daily for an additional 5 days, in combination with other B vitamins

KEEP IN MIND: administration of glucose without thiamine can precipitate or worsen WE; thus, thiamine should be administered before glucose.

Because GI absorption of thiamine is erratic in alcoholic and malnourished patients, oral administration of thiamine is an unreliable initial treatment for WE = IV infusion!

Be proactive in prophylaxis - for example, patients admitted for alcohol withdrawal should receive thiamine 100 - 250mg daily, depending on their nutritional status and perceived risk of WE

26
Q

Opioid use disorder

RF

A

Access to and availability of opioids
Previous exposure to substance use (e.g., having friends or family who use substances)
Current or past substance use disorder
Family history of substance use disorder
Having mental health conditions such as depression or post-traumatic stress disorder
History of abuse during childhood
History of conduct disorder as a child or adolescene

27
Q

Opioid abuse

Intoxication Sx

A

Euphoria
Sedation
Slurred speech
Constipation
Analgesia
Decreased respirations
Attentional deficits
Pinpoint pupils

28
Q

Opioid

Withdrawal Sx

A

Dysphoria, anxiety
Insomnia
Diarrhea, nausea, vomiting
Muscle and joint pain
Diaphoresis
Chills
Piloerection
Tearing
Yawning

Withdrawal is exceedingly uncomfortable, but not life-threatening

29
Q

Opioid withdrawal

Tx

A

Primary Treatments:
Buprenorphine
Methadone (specific license required)
Clonidine

Adjunctive treatments:
NSAIDS for pain
Kaopectate or immodium for diarrhea
Hydroxyzine for anxiety or insomnia
Benzodiazepines can be used, if needed
Decongestants for rhinorhea
Phenergan for nausea and vomiting
Avoid using needles

30
Q

Opioid Use Disorder

Treatment

A

For detox/withdrawal
Opioid agonists
Buprenorphine (partial)
Suboxone(+naloxone/narcan)
Subutex (bup only)
Bunavail (+naloxone/narcan)
Zubsolv (+naloxone/narcan)
Methadone (full)

For long term maintenance
Opioid antagonists
Naltrexone oral
Naltrexone IM (Vivitrol)
Buprenorphine
Methadone

31
Q

Opioid abuse

Methadone

A

Pure opioid agonist → greater OD risk than buprenorphine

Best studied and longest used medication for treatment of opioid addiction

Methadone maintenance therapy is associated with overall lower mortality rates, including 70% lower than untreated heroin abusers

Methadone is first line for pregnant patients with OUD
Must be administered by certified center, typically dosed daily

Works by:
Prevents cravings
Prevents withdrawal symptoms for 24+ hrs
reduces the euphoric effects of subsequent illicit opioid use by maintaining high levels of opioid tolerance

32
Q

OUD

Buprenorphine

A

Opioid partial agonist
Some pain relief, potential for diversion

Oral form combined with naloxone to decrease diversion to injection (Suboxone)

Long-acting injection available (Sublocade) and implant (Probuphine)
Patient should be experiencing withdrawal symptoms prior to starting (depends on half-life of drug)

Safe in pregnancy, but less research than methadone, so this is not first line

Patients are at higher risk of death if concurrently taking benzodiazepines, alcohol or using IV opiates in combination with Buprenorphine
Does not show up on standard drug screen

Contraindicated: severe hepatic impairment

33
Q

OUD

Naltrexone

A

Partial Opioid antagonist
comes in oral daily form and long acting injection (1 month)
Must be free from opioids or will enter precipitated withdrawal

Can be started 3-6 days after last use of short-acting opioids, 7-10 days after last use of long-acting opioids (methadone/bup)
Can do in-office naloxone challenge test

Side effects: nausea, headache, dizziness, fatigue, liver damage - this is rare (seen with supra-therapeutic doses) and resolves with discontinuation of naltrexone

Very high risk of OD if patient relapses. Educate!
Research in pregnancy is limited; discontinue unless risk of relapse is high

Contraindication: acute hepatitis and liver failure

34
Q

OUD

Naltrexone - special considerations

A
  • Emergency pain management: In naltrexone-treated patients requiring emergency pain management, consider alternatives to opioid therapy (eg, regional analgesia, nonopioid analgesics, general anesthesia). If opioid therapy is required for pain therapy, patients should be under the direct care of a trained anesthesia provider.
  • Surgery: In patients treated with naltrexone for opioid addiction who requiring surgery, discontinue oral naltrexone at least 72 hours before scheduled elective surgery if opioid use is anticipated; extended-release IM naltrexone should be discontinued at least 30 days prior to scheduled surgery (oral naltrexone may be used temporarily)
35
Q

OUD

Naloxone

A

total Opioid antagonist that blocks effects of opioid analgesics and reverses the effects of overdose

No abuse potential
Can be administered in both healthcare settings and in community

Project DAWN (Deaths Avoided with Naloxone)

Demonstrated to decrease mortality, not cause opioid dose escalation and improve eventual entry into treatment

36
Q

Cannabis Use Disorder

general

A

Cannabis is the most commonly used illegal psychoactive substance.

1 in 8 current regular cannabis users develops a cannabis use disorder

Cannabis use before age 17 years is strongly associated with lower educational attainment and increased use of other drugs

Cannabis acutely impairs attention, concentration, episodic memory, associative learning, and motor coordination in a dose-dependent manner
often use other psychoactive substances, especially alcohol and tobacco.

Chronic use associated with periodontal disease, hyperemesis, low sperm count and small increased risk of MI and stroke.

Substantial evidence suggests that chronic cannabis use, especially during adolescence, is associated with later development of schizophrenia

37
Q

cannabis

intox Sx

A

Intox
Conjunctival injection
Increased appetite
Dry mouth
Tachycardia
Specifier: with perceptual disturbances
Effects can last up to 24 hours before most cannabinoids are fat soluble

38
Q

Cannabis

Withdrawal - Sx

A

Irritability, anger, or aggression
Anxiety
Sleep difficulty
Decreased appetite or weight loss
Restlessness
Depressed mood
Abd pain, tremor, sweating, deveres, chills, headaches

39
Q

Stimulant

Intox Sx

A

Tachycardia OR bradycardia
Mydriasis
HTN or hypotension
Perspiration or chills
N/V
Evidence of weight loss
Psychomotor agitation or retardation
Muscle weakness, respiratory depression, chest pain, cardiac arrhythmias
Confusion, seizures, dyskinesias, dystonias, or coma
Specifier: with perceptual disturbances

40
Q

Stimulant

withdrawal Sx

A

Dysphoric mood - always present and required for diagnosis
Fatigue
Vivid, unpleasant dreams
Insomnia or hypersomnia
Increased appetite
Psychomotor retardation or agitation

41
Q

Sedative, Hypnotic, Anxiolytic Use Disorder

Intox Sx

Xanax
Valium
Ativan
Lunesta
Ambien
Belsomra
Rozerem
Halcion

A

Slurred speech
Incoordination
Unsteady gait
Nystagmus
Impairment in cognition - attention/memory
Anterograde amnesia
Stupor or coma

42
Q

Sedative, Hypnotic, Anxiolytic Use Disorder

Withdrawal Sx

A

Autonomic hyperactivity - diaphoresis, tachycardia
Hand tremor
Insomnia
N/V
Transient visual/tactile/auditory hallucinations
Psychomotor agitation
Anxiety
Grand mal seizures
Specifier: with perceptual disturbances
For the longer half-life meds (diazepam) - this can last for up to a month

43
Q

Phencyclidine Use Disorder

Intox Sx/ withdrawal Sx

PCP
Angel Dust
Ketamine

A

chronic use can lead to deficits in memory, speech, and cognition that may last for months

Vertical or horizontal nystagmus
HTN or tachycardia
Numbness or diminished responsiveness to pain
Ataxia
Dysarthria
Muscle rigidity
Seizures or coma
Hyperacusis

**If toxicity occurs → intracranial hemorrhage, rhabdo, cardiac arrest

Withdrawal- None!

44
Q

1. Hallucinogen Use Disorder

Intox / withdrawal Sx

Peyote
Psilocybin

LSD

A

Perceptual changes occurring in a state of full wakefulness and alertness- Depersonalization, derealization, illusions, hallucinations,
Mydriasis
Tachycardia
Diaphoresis
Palpitations
Blurring of vision
Tremors
Incoordination

Withdrawal - None!

45
Q

Hallucinogen Persisting Perception Disorder

A

Following cessation of use of a hallucinogen, the reexperiencing of one or more of the perceptual symptoms that were experienced while intoxicated with the hallucinogen

  • Geometric hallucinations, false perceptions of movement in the periphery, flashes of color, intensified colors, trails of images of moving objects, halos around objects, macropsia, micropsia
  • Visual disturbances are predominant, and can be episodic or continually present
  • Occurs primarily after LSD use, but not exclusively
  • Does not appear to be correlated with # of uses
46
Q

Inhalant Use Disorder

Intox/ Withdrawal Sx

Nitrous
Spray Paint
Butane
Markers
Glue
Cleaning sol.
AC refrigerant

A

Intox
Dizziness
Nystagmus
Incoordination
Slurred speech
Unsteady gait
Lethargy
Depressed reflexes
Psychomotor retardation
Tremor
Generalized muscle weakness
Blurred vision
Stupor, coma
Euphoria

Beware of “sudden sniffing death” which can occur when the inhalant causes cardiac arrhythmias

Withdrawal - None!

47
Q

Tobacco Intoxication / Withdrawal

Intox/ withdrawal Sx

A

Intox
No formal intox criteria

Withdrawal
Irritability, frustration, or anger
Anxiety
Difficulty concentration
Increased appetite
Restlessness
Depressed mood
Insomnia
Peaks at 2-3 days after abstinence and lasts 2-3 weeks

48
Q

Tobacco Use Disorder

treatment

A

Chantix/Varenicline
28 day treatment course
Day 1-3: 0.5 mg once daily
Day 4-7: 0.5 mg twice daily
Day 8-28: 1 mg twice daily
Reduces craving and withdrawal symptoms
Notorious for causing nightmares

Nicotine replacement
Patch, Gum, Lozenge, Spray, Inhaler
Dosing varies depending on how nicotine dependent the patient is - slowly decrease dose of nicotine replacement weekly until lowest dose is achieved (ie 21mg x 1 week, 14mg x 1 week, 7mg x 1 week, then stop)

Bupropion/Wellbutrin/Zyban
150-300mg XL once daily